Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Tinzaparin sodium (Innohep® Syringe) is recommended as an option for use within NHS Wales for the extended treatment of symptomatic venous thromboembolism and prevention of its recurrence in adult patients with solid tumours. |
|||
|
|||
Medicine details |
|||
| Medicine name | tinzaparin sodium (Innohep®) | ||
| Formulation | 20,000 units/ml solution for injection | ||
| Reference number | 2369 | ||
| Indication | Treatment of symptomatic venous thromboembolism and prevention of its recurrence in adult patients with solid tumours |
||
| Company | LEO Pharma | ||
| BNF chapter | Cardiovascular system | ||
| Assessment type | Limited | ||
| Status | Recommended | ||
| Advice number | 3715 | ||
| NMG meeting date | 07/10/2015 | ||
| AWMSG meeting date | 11/11/2015 | ||
| Ratification by Welsh Government | 09/12/2015 | ||
| Date of issue | 10/12/2015 | ||